Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US


Page 4

Amendments to the Claims:


This claim listing replaces all prior versions, and listings of claims in the application. Please amend the claims as follows:

1-39. (Previously cancelled)


40. (Currently amended) Compounds A compound of the general formula



wherein the template is selected from the group consisting of DPro-Pro and Pro-Pro;



is a group of one of the formulae



Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 5

is a group of one of the formulae

-B-CO- is Asn; Cys; Gln; His; Met; Phe; Pro; Ser; Thr; Trp; Tyr; Sar; $4\Delta mPhe$; $3\Delta mPhe$; $2\Delta mPhe$; Phe(mC(NH₂)=NH); Phe(pC(NH₂)=NH); Phe(mNHC (NH₂)=NH); Phe(pNHC (NH₂)=NH); Phg; Cha; C₄al; C₅al; 2-Nal; 1-Nal; 4Cl-Phe; 3Cl-Phe; 2Cl-Phe; 3,4Cl₂Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer; hPhe; Bpa;

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 6

Pip; OctG; MePhe; MeNle; MeAla; Melle; MeVal; or MeLeu; or B is a group, having (L)-configuration, of formula

wherein R²⁰ is H; or lower alkyl; and R⁶⁴ is alkyl; alkenyl; aryl; aryl lower alkyl; or heteroaryl lower alkyl;

R⁺ is hydrogen or lower alkyl;

R² is H; lower alkyl; lower alkenyl; (CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are -(CH₂)₂₋₆; (CH₂)₂O(CH₂)₂-;

-(CH₂)₂S(CH₂)₂-; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); (CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are

 $\frac{(CH_2)_{2\cdot 6} + (CH_2)_2O(CH_2)_2 + (CH_2)_2S(CH_2)_2 + or - (CH_2)_2NR^{57}(CH_2)_2 + where \ R^{57} \ is \ H; \ or \ lower \ alkyl);}{alkyl);}$

 $\begin{array}{l} -(CH_2)_mNR^{20}CONR^{33}R^{82} \text{ (where }R^{20} \text{ is H; or lower alkyl; }R^{33} \text{ is H; or lower alkyl; or lower alkyl; or lower alkyl; or }R^{33} \text{ and }R^{82} \text{ taken together are } -(CH_2)_{2\cdot6} \div -(CH_2)_2O(CH_2)_2 \div \\ -(CH_2)_2S(CH_2)_2 \div \text{ or } -(CH_2)_2NR^{57}(CH_2)_2 \div \text{ where }R^{57} \text{ is H; or lower alkyl);} \end{array}$

(CH₂)₀N(R²⁰)COR⁶⁴(where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH₂)₀COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); (CH₂)₀CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkyl; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)₂₋₆; (CH₂)₂₋₀(CH₂)₂; (CH₂)₂S(CH₂)₂; or

-(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 7

alkyl; or lower alkenyl); -(CH2), SO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2), C6H4R8 (where R8 is H; F; Cl; CF2; lower alkyl; lower alkenyl; or lower alkoxy); R³ is H; lower alkyl; lower alkenyl; (CH₂), OR (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); -(CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are (CH2)26; $\frac{(CH_2)_2O(CH_2)_2}{(CH_2)_2}$; $\frac{(CH_2)_2S(CH_2)_2}{(CH_2)_2}$; or $\frac{(CH_2)_2NR^{57}}{(CH_2)_2}$; where R^{57} is H; or lower alkyl); (CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R^{75} taken together are $(CH_2)_{2.6}$; $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2NR^{57}(CH_2)_2$ -; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R²³ and R⁸² taken together are (CH2)26-; -(CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); -(CH₂)_eN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH2)0COOR57 (where R57 is lower alkyl; or lower alkenyl); (CH2)0CONR58 R59 (where R58 is lower alkyl; or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)_{2.6}-; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); -(CH2)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); (CH₂)₀SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or (CH2), C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); R⁴ is H; lower alkyl; lower alkenyl; -(CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are (CH2)26; $\frac{(CH_2)_2O(CH_2)_2}{(CH_2)_2}$; $\frac{(CH_2)_2S(CH_2)_2}{(CH_2)_2}$; or $\frac{(CH_2)_2NR^{57}(CH_2)_2}{(CH_2)_2}$; where R^{57} is H; or lower alkyl); -(CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 8

(CH₂)₂₋₆-;

-(CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or -(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mN(R²⁰)COR⁶⁴(where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH₂)_oCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_oCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂ 6;

 $\frac{(CH_2)_2O(CH_2)_2 \cdot (CH_2)_2S(CH_2)_2 \cdot \text{or} \cdot (CH_2)_2NR^{57}(CH_2)_2 \cdot \text{where } R^{57} \cdot \text{isH; or lower alkyl);}}{(CH_2)_0PO(OR^{60})_2 \cdot (\text{where } R^{60} \cdot \text{is lower alkyl; or lower alkenyl);} \cdot (CH_2)_0SO_2R^{62} \cdot (\text{where } R^{62} \cdot \text{is lower alkenyl);}} \cdot (CH_2)_0C_0R^{60} \cdot (CH_2)_0C_0R$

 R^5 is lower alkyl; lower alkenyl; (CH₂)₀OR⁵⁵ (where R^{55} is lower alkyl; or lower alkenyl); (CH₂)₀NR³³R³⁴ (where R^{56} is lower alkyl; or lower alkenyl); (CH₂)₀NR³³R³⁴ (where R^{33} is lower alkyl; or lower alkyl; or R^{34} and R^{34} taken together are (CH₂)₂₋₆; (CH₂)₂O(CH₂)₂;

 $-(CH_2)_2S(CH_2)_2 ; or -(CH_2)_2NR^{57}(CH_2)_2 ; where R^{57} is H; or lower alkyl); -(CH_2)_eOCONR^{33}R^{75} \\ (where R^{33} is H; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken \\ together are$

-(CH₂)_{2·6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); (CH₂)₆NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkyl; or R³⁴ and R⁸² taken together are -(CH₂)_{2·6}; (CH₂)₂O(CH₂)₂;

 $\frac{(CH_2)_2S(CH_2)_2 \ ; or \ (CH_2)_2NR^{57}(CH_2)_2 \ ; where \ R^{57} \ is \ H; or lower alkyl); \ (CH_2)_6N(R^{20})COR^{64} }{(where: R^{20} \ is \ H; or lower alkyl; R^{64} \ is alkyl; alkenyl; aryl; aryl lower alkyl; or heteroaryl lower alkyl); \ (CH_2)_6COOR^{57} \ (where \ R^{57} \ is lower alkyl; or lower alkenyl); \ (CH_2)_6CONR^{58}R^{59} \ (where \ R^{58} \ is lower alkyl; or lower alkenyl; and R^{59} \ is \ H; or lower alkyl; or R^{58} \ and R^{59} \ taken together are \ (CH_2)_2 \ ; \ (CH_2)_2O(CH_2)_2 \ ; \ (CH_2)_2S(CH_2)_2 \ ; or \ (CH_2)_2NR^{57}(CH_2)_2 \ ; where \ R^{57} \ is \ H; or lower alkyl);$

-(CH2),PO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); (CH2),SO2R62 (where R62 is

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 9

lower alkyl; or lower alkenyl); or (CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);

 R^6 is H; lower alkyl; lower alkenyl; $(CH_2)_0OR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $(CH_2)_0SR^{56}$ (where R^{56} is lower alkyl; or lower alkenyl); $(CH_2)_0NR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkyl; or R^{33} and R^{34} taken together are $(CH_2)_2G^{55}$ ($CH_2)_2O(CH_2)_2$;

-(CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)₀OCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are

- $(CH_2)_2G_1$; $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); $(CH_2)_6NR^{20}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkyl; or R^{33} and R^{82} taken together are $(CH_2)_2G_2$; $(CH_2)_2O(CH_2)_2$;

-(CH₂)₂S(CH₂)₂-; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); -(CH₂)₆N(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH₂)₆COOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); (CH₂)₆CONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)₂₋₆-; (CH₂)₂O(CH₂)₂-; -(CH₂)₂S(CH₂)₂-; or

 $\frac{(CH_2)_2NR^{57}(CH_2)_2 \cdot \text{; where } R^{57} \text{ is H; or lower alkyl); } {(CH_2)_6PO(OR^{60})_2 \cdot \text{(where } R^{60} \text{ is lower alkyl}; \text{ or lower alkenyl}); } {(CH_2)_6SO_2R^{62} \cdot \text{(where } R^{62} \text{ is lower alkyl}; \text{ or lower alkenyl}); } {(CH_2)_6C_6H_4R^8 \cdot \text{(where } R^8 \text{ is H; F; Cl; CF}_3; \text{ lower alkyl; lower alkenyl}; \text{ or lower alkenyl}; } {(CH_2)_6OR^{55} \cdot \text{(where } R^{55} \text{ is lower alkyl; or lower alkenyl}; } {(CH_2)_6SR^{56} \cdot \text{(where } R^{56} \text{ is lower alkyl; or lower alkenyl}; } {(CH_2)_6NR^{33}R^{34} \cdot \text{(where } R^{33} \text{ is lower alkyl}; } {(CH_2)_2O(CH_2)_2 \cdot \text{;} } {(CH_$

 $-\frac{(CH_2)_2S(CH_2)_2 \div or \cdot (CH_2)_2NR^{57}(CH_2)_2 \div where \ R^{57} \ is \ H; \ or \ lower \ alkyl); \ \cdot (CH_2)_qOCONR^{33}R^{75}}{(where \ R^{33} \ is \ H; \ or \ lower \ alkyl; \ or \ lower \ alkenyl; \ R^{75} \ is \ lower \ alkyl; \ or \ R^{33} \ and \ R^{75} \ taken}$ together are

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 10

-(CH₂)₂₋₆-; (CH₂)₂O(CH₂)₂-; (CH₂)₂S(CH₂)₂-; or (CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH2)aNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R²³ and R⁸² taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂-; or (CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_eN(R²⁰)COR⁶⁴(where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH2), COOR57 (where R57 is lower alkyl; or lower alkenyl); (CH2), CONR58 R59 (where R58 is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH2)26-: (CH2)2O(CH2)2: (CH2)2S(CH2)2: or -(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂),PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH2), SO2R62 (where R62 is lower alkyl; or lower alkenyl); or (CH2) GAH4R8 (where R8 is H: F: Cl: CF2: lower alkyl; lower alkenyl; or lower alkoxy); R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; (CH2), OR55 (where R55 is lower alkyl; or lower alkenyl); (CH2), SR56 (where R56 is lower alkyl; or lower alkenyl); (CH2), NR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are (CH2)2 6-; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); -(CH₂)_eOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R⁷⁵ taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); (CH₂), NR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are (CH2)26-; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); -(CH₂)_eN(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH₂)_eCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_eCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)₂₋₆-; $-(CH_2)_2O(CH_2)_2$; $-(CH_2)_2S(CH_2)_2$; or $-(CH_2)_2NR^{57}(CH_2)_2$; where R^{57} is H; or lower alkyl); -(CH₂)_ePO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH₂)_eSO₂R⁶² (where R⁶² is

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 11

lower alkyl; or lower alkenyl); or (CH₂)_qC₆H₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);

R¹⁺ is H; lower alkyl; lower alkenyl; (CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)_mNR³²R³⁴ (where R³³ is lower alkyl; or lower alkenyl); (CH₂)_mNR³²R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are (CH₂)_{2.6}; (CH₂)_{2.0}(CH₂)_{2.7}; (CH₂)_{2.2}S(CH₂)_{2.7}; or (CH₂)₂NR⁵⁷(CH₂)_{2.7}; where R⁵⁷ is H; or lower alkyl); (CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R²⁵ is lower alkyl; or R³⁴ and R⁷⁵ taken together ar (CH₂)_{2.6}; (CH₂)_{2.0}(CH₂)_{2.7}; (CH₂)_{2.2}S(CH₂)_{2.7}; or (CH₂)_{2.2}NR⁵⁷(CH₂)_{2.7}; where R⁵⁷ is H; or lower alkyl); (CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; R³³ is H; or lower alkyl; R³³ is H; or lower alkyl; R³⁴ is H; or lower alkyl; or lower alkyl; R³⁵ is H; or lower alkyl; or R³⁵ and R⁸² taken together are (CH₂)_{2.6};

-(CH₂)₂O(CH₂)₂; -(CH₂)₂S(CH₂)₂; or -(CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mN(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); -(CH₂)_oCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); -(CH₂)_oCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are -(CH₂)_{2.6};

 $\frac{(CH_2)_2O(CH_2)_2 \ ; \ (CH_2)_2S(CH_2)_2 \ ; \ or \ (CH_2)_2NR^{57}(CH_2)_2 \ ; \ where \ R^{57} \ is \ H; \ or \ lower \ alkyl);}{(CH_2)_0PO(OR^{60})_2 \ (where \ R^{60} \ is \ lower \ alkyl; \ or \ lower \ alkenyl); \ (CH_2)_0SO_2R^{62} \ (where \ R^{62} \ is \ lower \ alkenyl);}$ where R^{62} is lower alkenyl); or CH_2 _0SO_2R^{62} \ (where \ R^{62} \ is \ H; F; Cl; CF_3; \ lower \ alkyl; \ lower \ alkenyl; \ or \ lower \ alkoxy);}

R¹² is H; lower alkyl; lower alkenyl; (CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; (CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R³⁴ taken together are (CH₂)_{2.6}; (CH₂)_{2.2}O(CH₂)_{2.2}; (CH₂)_{2.2}S(CH₂)_{2.2}; or (CH₂)₂NR⁵⁷(CH₂)_{2.5}; where R⁵⁷ is H; or lower alkyl); (CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R³⁵ taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)_{2.5}; (CH₂)_{2.2}S(CH₂)_{2.2}; or (CH₂)₂NR⁵⁷(CH₂)_{2.2}; where R⁵⁷ is H; or lower alkyl); (CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkyl; R³³ is H; or lower alkyl; or lower alkyl; or lower alkyl; or R³³ and R⁸² taken together are

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 12

(CH₂)₂₋₆-;

-(CH₂)₂O(CH₂)₂; -(CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); -(CH₂)_mN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH₂)_cCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); (CH₂)_cCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)_{2.6};

 $\frac{(CH_2)_2O(CH_2)_2 \cdot (CH_2)_2S(CH_2)_2 \cdot \text{or } (CH_2)_2NR^{57}(CH_2)_2 \cdot \text{where } R^{57} \text{ is H; or lower alkyl);}}{(CH_2)_2PO(OR^{60})_2 \cdot (\text{where } R^{60} \text{ is lower alkyl; or lower alkenyl);} \cdot (CH_2)_0SO_2R^{62} \cdot (\text{where } R^{62} \text{ is lower alkenyl);}}$ $\frac{(CH_2)_2PO(OR^{60})_2 \cdot (\text{ch}_2)_2SO_2R^{62} \cdot (\text{where } R^{62} \text{ is lower alkenyl});}{(CH_2)_0SO_2R^{62} \cdot (\text{where } R^{62} \text{ is lower alkenyl};} \cdot (CH_2)_0SO_2R^{62} \cdot (\text{where } R^{62} \text{ is lower alkyl};}$ $\frac{(CH_2)_2PO(OR^{60})_2 \cdot (\text{ch}_2)_2 \cdot ($

R²⁰ is H; or lower alkyl;

 R^{25} is H; lower alkyl; lower alkenyl; $(CH_2)_mOR^{55}$ (where R^{55} is lower alkyl; or lower alkenyl); $(CH_2)_mNR^{33}R^{34}$ (where R^{33} is lower alkyl; or lower alkenyl; R^{34} is H; or lower alkyl; or R^{33} and R^{34} taken together are $(CH_2)_2$ 6-; $(CH_2)_2O(CH_2)_2$ -; $(CH_2)_2S(CH_2)_2$ -; or $(CH_2)_2NR^{57}(CH_2)_2$ -; where R^{57} is H; or lower alkyl); $(CH_2)_mOCONR^{33}R^{75}$ (where R^{33} is H; or lower alkyl; or lower alkyl; or lower alkenyl; R^{75} is lower alkyl; or R^{33} and R^{75} taken together are $(CH_2)_2$ 6-; $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$ -; or

(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower alkenyl; R⁸² is H; or lower alkyl; or R³³ and R⁸² taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)_mN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH₂)_eCOOR⁵⁷ (where R⁵⁷ is lower alkyl; or lower alkenyl); (CH₂)_eCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)_{2.6}; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂-; or (CH₂)₂NR⁵⁷(CH₂)₂-; where R⁵⁷ is H; or lower alkyl);

- $(CH_2)_{\circ}PO(OR^{60})_2$ (where R^{60} is lower alkyl; or lower alkenyl); $(CH_2)_{\circ}SO_2R^{62}$ (where R^{62} is lower alkyl; or lower alkenyl); or - $(CH_2)_{\circ}C_6H_4R^8$ (where R^8 is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkoxy);

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 13

R²⁶ is H; lower alkyl; lower alkenyl; (CH₂), OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); -(CH₂)_mNR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R^{34} taken together are $(CH_2)_{2.6}$; $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2NR^{57}(CH_2)_2$; where R⁵⁷ is H; or lower alkyl); (CH₂)_mOCONR³³R⁷⁵ (where R³³ is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2-; or -(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)_mNR²⁰CONR³³R⁸² (where R²⁰ is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 $\frac{\text{taken together are } (CH_2)_{2\cdot 6} + (CH_2)_2 O(CH_2)_2 + (CH_2)_2 S(CH_2)_2 + \text{or } (CH_2)_2 NR^{57} (CH_2)_2 + \text{where}}{(CH_2)_2 + (CH_2)_2 O(CH_2)_2 + (CH_2)_2 S(CH_2)_2 + (CH_2)_2 O(CH_2)_2 + (CH_2)_2 O(CH_2$ R⁵⁷ is H; or lower alkyl); -(CH₂)_mN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH2), COOR57 (where R57 is lower alkyl; or lower alkenyl); (CH₂)_eCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁹ is H; lower alkyl; or R⁵⁸ and R^{59} -taken together are $(CH_2)_{2.6}$; $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2NR^{57}(CH_2)_2$ -: where R⁵⁷ is H; or lower alkyl); -(CH2)_oPO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); -(CH2)_oSO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or (CH2), C6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or lower alkoxy); or, alternatively, R25 and R26 taken together are -(CH2)26; (CH₂)₂O(CH₂)₂-: -(CH₂)₂S(CH₂)₂ ; or (CH₂)₂NR³⁴(CH₂)₂ ; R^{33} is H; alkyl, alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sNR^{34}R^{63}$; $-(CH_2)_m(CHR^{64})_sOCONR^{75}R^{82}; (CH_2)_m(CHR^{64})_sNR^{20}CONR^{78}R^{82};$ $\frac{(CH_2)_o(CHR^{64})_sCOR^{64};}{(CH_2)_o(CHR^{64})_sCONR^{58}R^{59};}\frac{(CH_2)_o(CHR^{64})_sPO(OR^{60})_2;}{(CH_2)_o(CHR^{64})_sPO(OR^{60})_2;}$ -(CH₂)_o(CHR⁶¹)_o SO₂R⁶²; or (CH₂)_o(CHR⁶¹)_oC₆H₄R⁸; R³⁴ is H; lower alkyl; aryl, or aryl-lower alkyl; R³³ and R³⁴ taken together can form: (CH₂)₂₋₆; (CH₂)₂O(CH₂)₂-; (CH₂)₂S(CH₂)₂-; or ———(CH₂)₂NR⁵⁷(CH₂)₂-; R⁵⁰ is H: lower alkyl; or aryl-lower alkyl; R⁵⁷ is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 14

R⁵⁸-is-H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl;

R⁵⁹ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

 R^{58} -and R^{59} -taken together can form: $(CH_2)_{2.6}$ -; $(CH_2)_2O(CH_2)_2$ -; $(CH_2)_2S(CH_2)_2$ -; or $(CH_2)_2NR^{57}(CH_2)_2$ -;

R⁶⁰ is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;

R⁶⁴ is alkyl; alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl; -(CH₂)_mOR⁵⁵; -(CH₂)_mNR²⁰CONR⁷⁸R⁸²; -(CH₂)_oCOOR³⁷; -(CH₂)_oNR⁵⁸R⁵⁹; or -(CH₂)_oPO(COR⁶⁰)₂;

R⁶² is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl lower alkyl;

 $R^{64} is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl; <math display="block"> \frac{(CH_2)_p(CHR^{64})_sOR^{65}; (CH_2)_p(CHR^{64})_sSR^{66}; or (CH_2)_p(CHR^{64})_sNR^{24}R^{63}; }{(CH_2)_p(CHR^{64})_sNR^{20}CONR^{78}R^{82}; (CH_2)_p(CHR^{64})_sNR^{20}CONR^{78}R^{82}; }$

Z and Z^1 are chains of n and, respectively, n' α -amino acid residues whereby either n is 4 and n' is 6 or n is 5 and n' is 7, the positions of said amino acid residues in said chain Z being counted starting from the N-terminal amino acid and the positions of said amino acid residues in said chain Z^1 being counted starting from the C-terminal amino acid, whereby these amino acid residues are, depending on their position in the chains, Gly, or Pro, or of one of the types

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 15

```
I. NR<sup>86</sup>CH<sub>2</sub>CO-:
R<sup>72</sup> is H, lower alkyl; lower alkenyl; (CH<sub>2</sub>), (CHR<sup>61</sup>), OR<sup>85</sup>; or (CH<sub>2</sub>), (CHR<sup>61</sup>), SR<sup>85</sup>;
R^{73} is (CH_2)_e R^{77}; (CH_2)_e O(CH_2)_e R^{77}; (CH_2)_e S(CH_2)_e R^{77}; or (CH_2)_e NR^{20} (CH_2)_e R^{77};
R^{74} is (CH_2)_pNR^{78}R^{79}; -(CH_2)_pNR^{77}R^{80}; -(CH_2)_pC(=NR^{80})NR^{78}R^{79}; -(CH_2)_pC(=NR^{80})NR^{78}R^{80}; -(CH_2)_pC(=NR^{80})NR^{80}; -(CH_2)_
----(CH_2)_{\theta}C(=NOR^{50})NR^{78}R^{79};
-----(CH<sub>2</sub>)_{b}C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)_{b}NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;
\frac{(CH_2)_{\mathfrak{p}}N - C(NR^{78}R^{80})NR^{79}R^{80}}{(CH_2)_{\mathfrak{p}}C_{6}H_{4}NR^{78}R^{79}}; \frac{(CH_2)_{\mathfrak{p}}C_{6}H_{4}NR^{77}R^{80}}{(CH_2)_{\mathfrak{p}}C_{6}H_{4}NR^{77}R^{80}};
-----(CH<sub>2</sub>)<sub>0</sub>C<sub>6</sub>H<sub>4</sub>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)<sub>0</sub>C<sub>6</sub>H<sub>4</sub>C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>79</sup>;
 -----(CH_2)_{\mathfrak{p}}C_6H_4C(-NNR^{78}R^{79})NR^{78}R^{79}; -(CH_2)_{\mathfrak{p}}C_6H_4NR^{89}C(-NR^{89})NR^{78}R^{79};
 _____(CH<sub>2</sub>),<sub>6</sub>C<sub>6</sub>H<sub>4</sub>N=C(NR<sup>78</sup>R<sup>80</sup>)NR<sup>79</sup>R<sup>80</sup>; -(CH<sub>2</sub>),O(CH<sub>2</sub>),<sub>m</sub>NR<sup>78</sup>R<sup>70</sup>; -(CH<sub>2</sub>),O(CH<sub>2</sub>),<sub>m</sub>NR<sup>77</sup>R<sup>80</sup>;
 -----(CH<sub>2</sub>)_{r}O(CH<sub>2</sub>)_{p}C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)_{r}O(CH<sub>2</sub>)_{p}C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>79</sup>;
 -----(CH<sub>2</sub>)_{*}O(CH<sub>2</sub>)_{*}C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)_{*}O(CH<sub>2</sub>)_{**}NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;
 _____(CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>79</sup>;
  <u>(CH₂),O(CH₂),C6H4C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>:</u>
  -----(CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>NR<sup>80</sup>C(-NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>),S(CH<sub>2</sub>),MR<sup>78</sup>R<sup>79</sup>;
  ————(CH<sub>2</sub>),S(CH<sub>2</sub>),,NR<sup>77</sup>R<sup>80</sup>; (CH<sub>2</sub>),S(CH<sub>2</sub>),C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;
  _____(CH<sub>2</sub>)<sub>6</sub>S(CH<sub>2</sub>)<sub>6</sub>C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)<sub>6</sub>S(CH<sub>2</sub>)<sub>6</sub>C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>;
   -----(CH<sub>2</sub>)<sub>r</sub>S(CH<sub>2</sub>)<sub>m</sub>NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>; -(CH<sub>2</sub>)<sub>r</sub>S(CH<sub>2</sub>)<sub>m</sub>N=C(NR<sup>78</sup>R<sup>80</sup>)NR<sup>79</sup>R<sup>80</sup>;
   ----(CH_2)_{r}S(CH_2)_{p}C_6H_4CNR^{78}R^{79}; (CH_2)_{r}S(CH_2)_{p}C_6H_4C(-NR^{80})NR^{78}R^{79};
   -----(CH_{2})_{r}S(CH_{2})_{p}C_{6}H_{4}C(=NOR^{50})NR^{78}R^{79}; -(CH_{2})_{r}S(CH_{2})_{p}C_{6}H_{4}C(=NNR^{78}R^{79})NR^{78}R^{79};
   \frac{(CH_2)_{r}S(CH_2)_{p}C_{6}H_{4}NR^{80}C(=NR^{80})NR^{78}R^{79};-(CH_2)_{p}NR^{80}COR^{64};-(CH_2)_{p}NR^{80}COR^{77};}{(CH_2)_{p}NR^{80}COR^{77};}
    -----(CH_2)_pNR^{80}CONR^{78}R^{79}; or -(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79};
   R<sup>75</sup> is lower alkyl; lower alkenyl; or aryl lower alkyl;
    R<sup>33</sup> and R<sup>75</sup> taken together can form: (CH<sub>2</sub>)<sub>2-6</sub>; (CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>-; (CH<sub>2</sub>)<sub>2</sub>S(CH<sub>2</sub>)<sub>2</sub>-; or
     ———(CH2)2NR<sup>57</sup>(CH2)2÷
    R<sup>75</sup> and R<sup>82</sup> taken together can form: (CH<sub>2</sub>)<sub>2.6</sub>; (CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>; (CH<sub>2</sub>)<sub>2</sub>S(CH<sub>2</sub>)<sub>2</sub>; or
     -----(CH2)2NR<sup>57</sup>(CH2)2-;
```

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 16

R77 is R87; or a heteroaryl group of one of the formulae

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 17

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 18

R78 is H; lower alkyl; aryl; or aryl lower alkyl;

R⁷⁸ and R⁸² taken together can form: (CH₂)_{2.6}-; (CH₂)₂O(CH₂)₂-; (CH₂)₂S(CH₂)₂-; or
(CH₂)₂NR⁵⁷(CH₂)₂-;

R79 is H; lower alkyl; aryl; or aryl lower alkyl; or

 R^{78} and R^{79} , taken together, can be $(CH_2)_{2.7}$; $(CH_2)_{2}O(CH_2)_{2}$; or $(CH_2)_{2}NR^{57}(CH_2)_{2}$;

R⁸⁰ is H; or lower alkyl;

R81 is H; lower alkyl; or aryl lower alkyl;

R⁸² is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

 $R^{33} \text{ and } R^{82} \text{ taken together can form: } (CH_2)_{2\cdot 6} \; ; \; (CH_2)_{2\cdot O}(CH_2)_{2} \; ; \; (CH_2)_{2\cdot S}(CH_2)_{2\cdot 7} \; ; \; or \; (CH_2)_{2\cdot O}(CH_2)_{2\cdot C} \; ; \; (CH_2)_{2\cdot O}(CH_2)_{2\cdot O}($

R⁸³ is H; lower alkyl; aryl; or NR⁷⁸R⁷⁹;

 $R^{84} \stackrel{\text{is}}{=} (CH_2)_p CONR^{78} R^{79}; \quad (CH_2)_p NR^{80} CONR^{78} R^{79}; \quad (CH_2)_p C_6 H_4 CONR^{78} R^{79}; \quad of \quad (CH_2)_p C_6 H_4 NR^{80} CONR^{78} R^{79};$

R⁸⁵ is lower alkyl; or lower alkenyl;

 $R^{86} \text{ is } R^{74}; \underbrace{\{(CH_2)_u - X\}_t \cdot (CH_2)_v NR^{78}}_{} R^{79}; \underbrace{\{(CH_2)_u - X\}_t \cdot (CH_2)_v - C(-NR^{80})NR^{78}}_{} R^{79}; \underbrace{X \text{ is } -O}_{}, \underbrace{NR^{20}}_{} - \underbrace{NR^{20}}_{} - \underbrace{S}_{} - \underbrace{OCOO}_{}, \underline{u} \text{ is } 1 - 3, t \text{ is } 1 - 6, v \text{ is } 1 - 3;}$

R⁸⁷-is phenyl, p hydroxyphenyl, 2 naphthyl, 1 naphthyl, 4 chlorophenyl, 3 chlorophenyl, 2-chlorophenyl, 3,4-dichlorophenyl, 4-fluorophenyl, 3 fluorophenyl, 2 fluorophenyl, p benzyloxyphenyl, p biphenyl or p benzylphenyl.

with the provise that in said chains Z and Z^+ of n and, respectively, $n'\alpha$ amino acid residues

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 19

- if n is 4 and n' is 6, the amino acid residues in positions 1 to 4 of the chain Z and in positions 1' to 6' of in chain Z^1 are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro Tyr or Arg;
 - P2: of type E or of type F L-citrulline (Cit) or Arg;
 - P3: of type F, or the residue is Pro Cys;
 - P4: of type $E \land rg-NH_2$;
 - P1': of type C or of type D or of type E or of type F, or the residue is Gly Lys or Arg;
 - P2': of type D or of type C <u>Tyr</u>;
 - P3': of type F or the residue is Pro Cys;
 - P4': of type D or of type C L-2-naphthylalanine (2-Nal);
 - P5': of type E, or of type F or the residue is Pro Arg; and
 - P6': of type E or of type F, or the residue is Pro Arg; or
 - Cys at P3 and P3', taken together, can form a group of type H disulfide bridge;

and

- if n is 5 and n' is 7, the amino acid residues in positions 1 to 5 of in chain Z and in positions 1' to 7' of in chain Z^1 are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro Tyr;
 - P2: of type E or of type F Arg;
 - P3: of type F, or the residue is Pro Cit;
 - P4: of type F Cys;

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 20

- P5: of type E <u>Λrg or Arg-NH</u>₂
- P1': of type C or of type D or of type E or of type F, or the residue is Pro Lys;
- P2': of type F Cit;
- P3': of type D or the residue is Pro <u>Tyr</u>;
- P4': of type E or of type F Cys;
- P5': of type D, or the residue is Pro 2-Nal, Trp, L-para-aminophenylalanine (F(pNH₂)) or L-6-Cl-Tryptophan (W(6-Cl));
- P6': of type E or of type F, or the residue is Pro Arg; and
- P7': of type E or of type I, or the residue is Gly DArg, Arg, Ac-Arg, iPr-Arg N-(2-aminocthyl)glycine ((EA)G), N-(3-aminopropyl)glycine ((PrA)G), N-(4-amino-n-butyl)glycine ((BA)G), N-(2-guanidinocthyl)glycine ((EGU)G), N-(3-guanidino-n-propyl)glycine ((PrGU)G), or N-(4-guanidino-n-butyl)glycine ((BGU)G); or Cys at P4 and P4' can form a disulfide bridge

P2 and P2' and/or P4 and P4', taken together, can form a group of type H;

at P7' also D-isomers being possible,

and an enantiomer thereof and pharmaceutically acceptable salts thereof.

- 41-46. (Previously cancelled)
- 47-49. (Cancelled)
- 50. (Currently amended) Compounds The compound according to claim 48 $\underline{40}$, wherein the α -amino acid residues in positions 1 to 4 of the chain Z and the α -amino acid residues in positions 1' to 6' chain Z¹ are:

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 21

P1: Tyr, or Arg;

P2: Cit, or Arg;

- P3: Cys;

- P4: $Arg-NH_2$;

- P1': Lys, orArg;

- P2': Tyr;

- P3': Cys;

- P4': 2-Nal;

- P5': Arg;

P6': Arg; and

Cys at P3 and P3' can form a disulfide bridge.

51. (Currently amended) Compounds The compound according to claim 49 $\underline{40}$, wherein the α -amino acid residues in positions 1 to 5 of the chain Z and the α -amino acid residues in positions 1' to 7' chain Z^1 are:

```
P1: Tyr;
```

P2: Arg;

- P3: Cit;

- P4: Cys;

- P5: Arg, or Arg-NH₂;

- P1': Lys;

- P2': Cit;

- P3': Tyr;

- P4': Cys;

P5': 2-Nal, Trp, F(pNH₂), or W(6-Cl);

- P6': Arg;

P7': DArg, Arg, Ac-Arg, iPr-Arg, (EA)G, (PrA)G, (BA)G, (EGU)G, (PrGU)G, or (BGU)G; and

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 22

Cys at P4 and P4' can form a disulfide bridge.

- 52. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;
 - P2': Cit;
 - P3': Tyr;
 - P4': Cys;
 - P5': 2-Nal;
 - P6': Arg; and
 - P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- 53. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 23

P2': Cit;

- P3': Tyr;

- P4': Cys;

- P5': 2-Nal;

- P6': Arg; and

- P7': Ac-Arg; and

Cys at P4' and P4 forming a disulfide bridge.

54. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

P1: Tyr;

- P2: Arg;

. P3; Cit;

- P4: Cys;

- P5: Arg- NH_2 ;

- P1': Lys;

- P2': Cit;

- P3': Tyr;

- P4': Cys;

P5': 2-Nal

- P6': Arg; and

- P7': ^DArg; <u>and</u>

Cys at P4' and P4 forming a disulfide bridge.

55. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ${}^{D}\text{Pro-}{}^{L}\text{Pro}$, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z^{1} are:

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 24

- P1: Tyr;
- P2: Arg;
- P3: Cit;
- P4: Cys;
- P5: Arg- NH_2 ;
- P1': Lys;
- P2': Cit;
- P3': Tyr;
- P4': Cys;
- P5': $Phe(pNH_2)$;
- P6': Arg; and
- P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- 56. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - Pl: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;
 - P2': Cit;
 - P3': Tyr;
 - P4': Cys;
 - P5': 2-Nal;
 - P6': Arg; and

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 25

(PrA)G; and P7':

Cys at P4' and P4 forming a disulfide bridge.

- (Currently amended) A The compound of formula I according to claim 40, wherein the 57. template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z^1 are:
 - Tyr; P1:
 - Arg; P2:
 - Cit; P3:
 - P4: Cys;
 - P5: Arg;
 - P1': Lys;
 - P2': Cit;
 - P3': Tyr;
 - P4': Cys;
 - 2-Nal; P5':
 - P6': Arg; and
 - P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- (Currently amended) Enantiomers of the compounds of formulae I as defined in 58. claim 40.
- 59.-60. (Cancelled)
- (Previously presented) A pharmaceutical composition containing a compound according 61. to claim 40 and a pharmaceutically inert carrier.

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 26

- 62. (Currently amended) Compositions A composition according to claim 61 in a form suitable for a mode of administration selected from the group consisting of oral, topical, transdermal, injection, buccal, transmucosal, pulmonary and inhalation.
- 63. (Currently amended) Compositions A composition according to claim 61 in a form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
- 64. (Currently amended) Compositions A composition according to claim 62 in a form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
- 65. (Currently amended) A method for treating and/or preventing a disorder selected from the group consisting of HIV infections, cancer and inflammatory disorders, the method comprising mediated by or resulting from CXCR4 activity which comprises:

administering to a subject in need thereof of such treatment an effective amount of a compound according to claim 40.

- 66. (Currently amended) A process for the manufacture of compounds according to claim 40, which process comprises
- coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 4 of Z if n is 4 or in position 5 of Z if n is 5, any functional group which may be present in said N protected amino acid derivative being likewise appropriately protected;
- (b) removing the N-protecting group from the product thus obtained;
- (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in Z of the desired end-product is one position nearer the N-terminal amino

Amendment and Response dated February 16, 2010


Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US


Page 27

acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (d) removing the N-protecting group from the product thus obtained;
- (e) repeating steps (c) and (d) until the N-terminal amino acid residue of Z has been introduced;
- (f) coupling the product thus obtained with a compound of the general formula



wherein



is as defined in claim 40 and X is an N-protecting group; or, alternatively,

(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula

wherein B and A are as defined in claim 40 LPro or DPro, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (fb) removing the N-protecting group from the product thus obtained; and
- of an amino acid of the above general formula IV and, respectively, III DPro and, respectively, LPro, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 28

- (g) removing the N-protecting group from the product obtained in step (f) or (fc);
- (h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 1 of Z¹, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (i) removing the N-protecting group from the product thus obtained;
- (j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 1 of Z^1 , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (k) removing the N-protecting group from the product thus obtained;
- (l) repeating steps (j) and (k) until all amino acid residues of Z¹ have been introduced;
- (m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (n) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (o) detaching the product thus obtained from the solid support and removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
- (p) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.
- 67. (Currently amended) A process according to claim 66, but wherein an amino acid residue of type I a residue of glycine having the amino group substituted by a chain having a polar-cationic residue is introduced by coupling with a leaving group-containing acetylating acylating agent, followed by nucleophilic displacement with an amine of the formula H₂NR⁸⁶ having the amino group substituted by a chain having a polar-cationic residue which, if necessary, is appropriately protected.

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 29

- 68. (Currently amended) A process according to claim 67 wherein the leaving group in said leaving group-containing acetylating acylating agent is bromo, chloro or iodo acetic acid.
- 69. (Currently amended) A modification of the process according to claim 66 for the manufacture of compounds according to claim 56 58 in which enantiomers of all chiral starting materials are used.
- 70. (Currently amended) A modification of the process according to claim 67 for the manufacture of compounds according to claim 56 58 in which enantiomers of all chiral starting materials are used.